3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other
1
Head & Neck
1
Conditions
Lymphoma
2
Stomatitis
1
Neuroendocrine Tumors
1
Neoplasms
1
Mucositis
1
Mouth Neoplasms
1
Lung Neoplasms
1
Head and Neck Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Small Cell
1
Carcinoma, Ovarian Epithelial
1
Carcinoma, Non-Small-Cell Lung
1
Brain Neoplasms
1
Interventions
Radiotherapy
8
Cisplatin
8
Cetuximab
8
pembrolizumab
5
Fluorouracil
5
Drug Therapy
5
Surveys and Questionnaires
4
Celecoxib
4
Radiotherapy, Intensity-Modulated
3
Radiation
3
Sentinel Lymph Node Biopsy
2
Psychiatric Rehabilitation
2
Polymerase Chain Reaction
2
Physical Therapy Modalities
2
Nicotine
2
Interviews as Topic
2
Injections
2
Immunohistochemistry
2
High-Energy Shock Waves
2
Counseling
2
Chemoradiotherapy
2
Bupropion
2
Aminolevulinic Acid
2
trametinib
1
traY protein, E coli
1
toripalimab
1
sodium thiosulfate
1
sargramostim
1
motexafin gadolinium
1
mogamulizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Mouth Neoplasms
×
RRx-001
×
Clear all
NCT03515538
2024-11-04
PREVLAR
EpicentRx, Inc.
Phase 2
Completed
53 enrolled
15 charts